Fig. 3: Association between cardiovascular-kidney-metabolic syndrome stages and all-cause/cardiovascular mortality in NHANES Ⅲ cohort. | Communications Medicine

Fig. 3: Association between cardiovascular-kidney-metabolic syndrome stages and all-cause/cardiovascular mortality in NHANES Ⅲ cohort.

From: Cardiovascular-kidney-metabolic (CKM) syndrome is associated with increased mortality in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD)

Fig. 3

A All-cause mortality; B Cardiovascular mortality; a Overall cohort; b Patients aged <60 years; c Patients aged ≥60 years. Note: Hazard ratios were estimated using Cox proportional hazards regression models (two-sided tests). No adjustments were made for multiple comparisons. Multivariable model: adjusted for sex, age (not adjusted for age subgroup), poverty income ratio, ethnicity, and fibrosis-4 index; Adjusted for IPTW: the multivariable model was adjusted after IPTW. The central marker represents the hazard ratio (point estimate), and the error bars indicate the 95% confidence intervals. A (a): total number, n = 2159; stage 1, n = 335; stage 2, n = 1667; stages 3 and 4, n = 157. A (b): total number, n = 1631; stage 1, n = 306; stage 2, n = 1,269; stage 3–4, n = 56. A (c): total number, n = 528; stage 1, n = 29; stage 2, n = 398; stage 3–4, n = 101. B (a): total number, n = 1623; stage 1, n = 298; stage 2, n = 1238; stages 3 and 4, n = 87. B (b): total number, n = 1383; stage 1, n = 281; stage 2, n = 1067; stage 3–4, n = 35. B (c): total number, n = 240; stage 1, n = 17; stage 2, n = 171; stage 3–4, n = 52. IPTW inverse probability of treatment weighting, HR hazard ratio, 95% CI 95% confidence interval.

Back to article page